menu
    • menu
    [{"orgOrder":0,"company":"Eikon Therapeutics","sponsor":"Lux Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Series D Financing","leadProduct":"EIK1001","moa":"||TLR7\/8","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Eikon Therapeutics","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.34999999999999998,"dosageForm":"Intravenous Injection","sponsorNew":"Eikon Therapeutics \/ Lux Capital","highestDevelopmentStatusID":"9","companyTruncated":"Eikon Therapeutics \/ Lux Capital"}]

    Find Clinical Drug Pipeline Developments & Deals by Eikon Therapeutics

    Menu

    Eikon Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Eikon Therapeutics

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Eikon Therapeutics

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EIK1001,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Lux Capital

                            Deal Size : $350.7 million

                            Deal Type : Series D Financing

                            DEALS_DEV arrow-down

                            Eikon Secures $350.7M Series D to Advance Clinical Programs, Future Pipeline

                            Details : The financing aims to advance the company's pipeline, which includes lead product EIK1001, a systemically administered co-agonist of toll-like receptors 7/8 now in a Phase III for advanced melanoma.

                            Product Name : EIK1001

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            February 26, 2025

                            Lead Product(s) : EIK1001,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Lux Capital

                            Deal Size : $350.7 million

                            Deal Type : Series D Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth